Schizophrenia Research
Volume 98, Issue 1 , Pages 40-46 , January 2008

Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels

  • Jose de Leon

      Affiliations

    • University of Kentucky Mental Health Research Center at Eastern State Hospital, and University of Kentucky Colleges of Medicine and Pharmacy, Lexington, Kentucky, United States
    • Department of Psychiatry and Institute of Neurosciences, University of Granada, Granada, Spain
    • Corresponding Author InformationCorresponding author. Mental Health Research Center at Eastern State Hospital, 627 West Fourth St., Lexington, KY 40508, United States. Tel.: +859 246 7563; fax: +859 246 7019.
    • ,
  • Juan Carlos Correa

      Affiliations

    • Department of Statistics, Universidad Nacional, Medellín, Colombia
    • ,
  • Gualberto Ruaño

      Affiliations

    • Genomas, Inc., Hartford, Connecticut, United States
    • ,
  • Andreas Windemuth

      Affiliations

    • Genomas, Inc., Hartford, Connecticut, United States
    • ,
  • Maria J. Arranz

      Affiliations

    • Psychological Medicine, Institute of Psychiatry, King's College, London, United Kingdom
    • ,
  • Francisco J. Diaz

      Affiliations

    • Department of Statistics, Universidad Nacional, Medellín, Colombia

Received 6 August 2007 ,Revised 4 October 2007 ,Accepted 10 October 2007.

References 

  1. Agresti A. Categorical Data Analysis. New York: John Wiley & Sons; 1990;
  2. de Leon J, Diaz FJ. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. Schizophr. Res. 2007;96:185–197
  3. de Leon J, Susce MT, Johnson M, Hardin M, Pointer L, Ruaño G, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr. Res. 2007;92:95–102
  4. Ellingrod VL, Bishop JR, Moline J, Lin YC, Miller DD. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol. Bull. 2007;40:57–62
  5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. JAMA. 2002;287:356–359
  6. Harwood JH. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Exp. Opin. Ther. Targets. 2005;9:267–281
  7. Koch W, Hoppman P, Mueller JC, Schomig A, Kastrini A. Association of transforming growth factor-Beta1 gene polymorphisms with myocardial infarction in patients with angiographically proven coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 2006;26:1114–1119
  8. Kolsch H, Lutjohann D, Jessen F, Urbach H, von Bergmann K, Maier W, et al. Polymorphism in neuropeptide Y influences CSF cholesterol levels but is not a major risk factor for Alzheimer's disease. J. Neural Transm. 2006;113:231–238
  9. Kusunoki J, Kanatani A, Moller DE. Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndome. Endocrine. 2006;29:91–100
  10. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005;353:1209–1223
  11. Markham-Abedi C, de Leon J. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report (letter). J. Clin. Psychiatry. 2006;67:1473–1474
  12. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 2004;70:1–17
  13. Pearson TA. The epidemiologic basis for population-wide cholesterol reduction in the primary prevention of coronary artery disease. Am. J. Cardiol. 2004;94:4F–8F
  14. R Development Core Team, 2005. R. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org.
  15. Ruaño G, Goethe JW, Caley C, Woolley S, Holford TR, Kocherla M, et al. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol. Psychiatry. 2007;12:474–482
  16. Sasaki J, Funakoshi M, Arakawa K. Lipids and apolipoproteins in patients treated with major tranquilizers. Clin. Pharmacol. Ther. 1985;137:684–687
  17. SPSS, Inc. . SPSS Advanced Statistics 7.5. Chicago, IL: SPSS, Inc.; 1997;
  18. Turtzo LC, Lane MD. NPY and neuron-adipocyte interactions in the regulation of metabolism. EXS. 2006;95:133–141
  19. Woodward M. Epidemiology: Study Design and Data Analysis. Boca Raton, FL: Chapman & Hall/CRC; 1999;

PII: S0920-9964(07)00456-2

doi: 10.1016/j.schres.2007.10.003

Schizophrenia Research
Volume 98, Issue 1 , Pages 40-46 , January 2008

Article Tools